Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 2/20 | 0.37 |
| ▸ | F10 | P00742 | 2/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6437334 | 0.89 | ROCK2 (0.49) | ROCK2ALDH1A1POLB | |
| Trifluoroacetic Acid SCHEMBL7450905 | 0.84 | CA2 (0.44) | ROCK2ACECA1CA2 | |
| SCHEMBL7391218 | 0.81 | ROCK2 (0.34) | ROCK2ALDH1A1POLB | |
| Trifluoroacetic Acid SCHEMBL7372438 | 0.79 | GRN (0.45) | CA1CA2 | |
| SCHEMBL7370207 | 0.78 | CASP3 (0.46) | PRSS1CA1CA2 | |
| SCHEMBL7369532 | 0.78 | ITGB3 (0.46) | ROCK2ROCK1 | |
| SCHEMBL6432699 | 0.78 | GRN (0.38) | ROCK2 | |
| Trifluoroacetic Acid SCHEMBL7368235 | 0.76 | CA2 (0.40) | CA1CA2 | |
| SCHEMBL6433230 | 0.76 | ROCK2 (0.41) | ROCK2ROCK1TACR3F2F10 | |
| Trifluoroacetic Acid SCHEMBL7377943 | 0.76 | TMPRSS15 (0.44) | PRSS1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | CTSL 183/4885CYP26A1 2378/4885ROCK2 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.